ACM Biosciences

Bronze Sponsor

ACM Biolabs is a biotechnology company that is using its proprietary polymer-based nanoparticle delivery platform to develop new formulations for use in multiple therapeutic fields.

ACM Biolabs' Tunable Platform (ATP™) is a polymer/lipid hybrid, non-viral delivery platform that offers the flexibility to deliver multiple payloads including oligonucleotides, small molecules, proteins, and mRNA. ATP™ is thermostable, allowing mRNA storage at 4°C in contrast to the current lipid nanoparticle-based delivery systems that require ultra-low cold storage. ACM Biolabs has programs targeting multiple organs, tissues, and immune cells.

The Company has a growing pipeline of discovery and development-stage product formulations targeting numerous therapeutic areas including infectious diseases, oncology, and ophthalmology. ACM’s first clinical-stage development program ACM-001, is an adjuvanted SARS-CoV-2 spike protein (beta variant) vaccine and the company is seeking a partner to develop an mRNA vaccine. The Company has several oncology products including a program for solid tumors targeting a Toll-like receptor (TLR) and a lung cancer program. In ophthalmology, ACM Biolabs is exploring a specialized formulation suitable for topical application to the retina.

ACM Biolabs was founded in 2013 in Singapore. It has subsidiaries in Basel, Switzerland, and Sydney, Australia. The Phase I trial of ACM-001 was undertaken by ACM Biolabs’ wholly-owned Australian subsidiary, ACM Biolabs Pty Ltd.

For further information, please visit: